Dr Rimawi speaks with ecancertv at SABCS 2016 about the results of a trial in which neoadjuvant TCHP chemotherapy was administered alongside oestrogen deprivation therapy in HR/HER positive breast cancer patients.

He considers comments that the chemotherapy regimen seems to blunt the clinical benefit of anti-oestrogens, which may in turn be attributable to the sheer success of chemotherapy, or be influenced by the timing and dosage of the regimens.